- Report
- May 2023
- 200 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- October 2023
- 181 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- March 2024
- 198 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- January 2024
- 200 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Drug Pipelines
- April 2024
- 150 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Clinical Trials
- April 2024
- 450 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €2889EUR$3,000USD£2,485GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Clinical Trials
- April 2024
- 280 Pages
Global
From €2889EUR$3,000USD£2,485GBP
- Report
- January 2024
- 200 Pages
Global
From €3996EUR$4,150USD£3,437GBP
- Newsletter
- May 2024
- 88 Pages
Global
€1269EUR$1,318USD£1,092GBP
- Report
- January 2024
- 101 Pages
North America
From €1445EUR$1,500USD£1,242GBP
- Report
- January 2022
- 60 Pages
Global
From €3804EUR$3,950USD£3,271GBP
- Report
- August 2020
- 80 Pages
Global
From €2648EUR$2,750USD£2,278GBP
- Report
- February 2023
- 166 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Report
- August 2022
- 117 Pages
Global
From €4334EUR$4,500USD£3,727GBP
- Report
- April 2021
China
From €2504EUR$2,600USD£2,153GBP
- Report
- April 2021
- 51 Pages
Global
€1269EUR$1,318USD£1,092GBP
- Report
- January 2019
- 58 Pages
Global
From €9630EUR$10,000USD£8,282GBP
Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin lymphoma that arises from the outer edge of a lymph node follicle (the mantle zone) and is characterized by the malignant growth of B lymphocytes. Within the broader context of lymphoma drugs, the market for MCL treatments is focused on addressing the aggressive nature of the condition, which often makes standard chemotherapy less effective. The therapeutic landscape for MCL includes a variety of approaches such as targeted therapies, immunotherapy, combination therapies, and stem cell transplantation.
In recent years, the MCL market has seen the introduction of novel agents that target specific pathways involved in the pathogenesis of the disease. These agents include kinase inhibitors, proteasome inhibitors, and monoclonal antibodies, some of which have been granted breakthrough therapy designations for providing improved outcomes over traditional treatment options. Additionally, the treatment paradigm for MCL is shifting toward personalized medicine, considering the genetic profile of the patient's cancer to inform therapy choices.
Several pharmaceutical and biotechnology companies are active in the MCL market. Among these are Janssen Biotech, which markets ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor; AstraZeneca, with acalabrutinib, another BTK inhibitor; Bayer, the company behind the proteasome inhibitor copanlisib; AbbVie, co-developing venetoclax, a BCL-2 inhibitor Show Less Read more